[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 12 sources · 2 days · First seen · Last updated

Expansion of semaglutide generic and biosimilar markets

Overview

The pharmaceutical market for semaglutide-based medications is expanding through the introduction of generic and biosimilar alternatives. In Brazil, the National Health Surveillance Agency (Anvisa) approved new injectable semaglutide treatments for type 2 diabetes, including the country’s first official generic registered by EMS and a similar medication by Germed.

This increase in competition follows the expiration of patents for reference drugs. Domestic manufacturers like EMS have seen significant growth, with the Ozivy pen reporting sales of 200,000 units in July.

Concurrently, the company Sandoz is focusing on biosimilar growth, noting that these products accounted for 33 percent of its total revenue in the first half of 2026. Sandoz has also received approval in Brazil for its semaglutide product, Owozy, with sales expected to commence in the second half of the year.

Entities

Semaclique · Brazil · Novo Nordisk · Ozivy · EMS

Timeline

  1. 8 days ago

    [BUSINESS] 2 sources
    Sandoz targets biosimilar growth and generic semaglutide expansion

    Sandoz is pivoting toward biosimilars as a major growth engine, targeting the expanding market for generic semaglutide following significant stock gains and patent expirations.

  2. 10 days ago

    [BUSINESS] 10 sources
    Anvisa approves new semaglutide injectables and Brazil's first generic

    Anvisa has approved new semaglutide injectables in Brazil, including the first official generic, aimed at treating type 2 diabetes and increasing market competition.

Sources

aquiacontece.com.br · blog.estrategiavestibulares.com.br · brasilemfolhas.com.br · cash.ch · folhadoprogresso.com.br · infomoney.com.br · it-boltwise.de · mixvale.com.br · obomdanoticia.com.br · revistadafarmacia.com.br · veja.abril.com.br · viagemegastronomia.com.br